Checkpoint Therapeutics (NASDAQ:CKPT) Shares Down 1%

Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) fell 1% during mid-day trading on Tuesday . The stock traded as low as $1.42 and last traded at $1.44. 352,028 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 541,909 shares. The stock had previously closed at $1.45.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Checkpoint Therapeutics in a research report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $22.60.

Checkpoint Therapeutics Trading Down 1.4 %

The business has a 50 day moving average price of $1.92 and a 200-day moving average price of $2.05. The company has a market cap of $50.68 million, a P/E ratio of -0.43 and a beta of 0.99.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.36). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.09 million. On average, sell-side analysts expect that Checkpoint Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its position in shares of Checkpoint Therapeutics by 92.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock valued at $26,000 after buying an additional 5,375 shares during the last quarter. Choreo LLC acquired a new stake in Checkpoint Therapeutics during the 4th quarter valued at $44,000. Magnus Financial Group LLC bought a new position in Checkpoint Therapeutics during the fourth quarter worth $55,000. B. Riley Wealth Advisors Inc. increased its holdings in shares of Checkpoint Therapeutics by 9.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 49,150 shares of the company’s stock valued at $84,000 after purchasing an additional 4,205 shares during the last quarter. Finally, Park Avenue Securities LLC bought a new position in shares of Checkpoint Therapeutics in the third quarter valued at about $102,000. Institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.